Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06395948 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating APG777 in Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Apogee Therapeutics.

Active
Registry status
Phase 2
Development phase
470
Enrollment target
20
Study locations

NCT06395948: Active Phase 2 study of Atopic Dermatitis, sponsored by Apogee Therapeutics.

NCT06395948 is a Phase 2 study of Atopic Dermatitis that is active but no longer recruiting, run by Apogee Therapeutics. The registered enrollment target is 470 participants, below the 606-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06395948, a Phase 2 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Apogee Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
470 participants
Enrollment target
20
Study locations

Study Summary

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG Placebo
  • DRUG APG777

Study Locations (20)

California

  • Investigational Site - Fountain Valley
  • Investigational Site - Los Angeles
  • Investigational Site - San Diego

Florida

  • Investigational Site - Coral Gables
  • Investigational Site - Jacksonville
  • Investigational Site - Margate

Illinois

  • Investigational Site - Chicago
  • Investigational Site - Skokie

Michigan

  • Investigational Site - Detroit
  • Investigational Site - Troy

Ohio

  • Investigational Site - Boardman
  • Investigational Site - Mason

Connecticut

  • Investigational Site - New Haven

Georgia

  • Investigational Site - Douglasville

Indiana

  • Investigational Site - West Lafayette

Trial Details

FieldValue
Enrollment Target 470 participants
Start Date 2024-04-29
Est. Completion 2028-06
Phase Phase 2
Apogee Therapeutics

3 total trials

What the registry record for NCT06395948 still lists

NCT06395948 is an interventional study that assigns participants to a tested intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 606-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (22% lower).

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06395948 names 20 study sites across 13 states, led by California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06395948 about?

NCT06395948 is a clinical study titled "A Study Evaluating APG777 in Atopic Dermatitis". This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777...

What is the current status of trial NCT06395948?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 470 participants. The study started on 2024-04-29. Estimated completion is 2028-06.

What conditions does trial NCT06395948 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT06395948?

The interventions under investigation include: Placebo (DRUG), APG777 (DRUG).

Who is sponsoring clinical trial NCT06395948?

This trial is sponsored by Apogee Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06395948 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06395948's enrollment target sits among peer trials

470 27th of 150 higher than 124 of 150 other Atopic Dermatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05256940 · 470 participants · NA

    Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide

  • NCT05458219 · 470 participants · Phase 1

    A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

  • NCT05850689 · 470 participants · Phase 3

    Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  • NCT05935384 · 470 participants

    SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06395948, the US trial registry maintained by the National Library of Medicine. NCT06395948 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.